



Article 43 applications including comparative assessment – industry's role in managing the process

CEUREG ,

Zagreb, November 2015

Dr. Martyn Griffiths, Bayer SAS

Chairman of the ECPA Regulatory Policy Team

Content

- ▶ **Renewal Program and Article 43 process**
- ▶ **Candidates for Substitution and comparative assessment**
- ▶ **Revision of Regulation 1107/2009**



Renewal program: Key concerns

- Challenging timelines for evaluation (30 months) of actives
 - AIR1 and 2 significant delays
 - AIR3 More than 50% substances delayed
 - AIR4 uncertainty: No RMS defined yet

Article 43 process

- Timelines for submissions
- Mixture products should only be reviewed once!
- What are the timelines with AIR 2 & 3 delays?
- **Planning is a real challenge for MS and industry**

Innovation should not be delayed due to the renewal program

Solutions for product renewal




- ▶ **Commission decided not to revise Article 43**
 - Change will only come with Revision of Regulation (Earliest 2017 ?)
- ▶ **Need to rely on guidance document**
 - Unpredictability in Member States implementation
- ▶ **Amended guidance adopted in July SANTE/2010/13170 rev.13**
 - Reviewed in COM workshop in Dublin 2-4 June 2015
 - To be revised according to experience (section 1)
- ▶ **Category 4 studies: seasonal studies**
 - Data related to new endpoint but insufficient time to be generated
 - Submit asap considering time necessary to conduct studies (~2 years)

**Improved but still numerous uncertainties
Member States need to implement pragmatically!**

Assessment of mixture products



- ▶ ECPA have proposed that mixture products should only be evaluated once
-but only possible if substances expire within 1 year
- ▶ If substances expire within 1 year, then product submission linked to 2nd active substance
- ▶ Products containing 2+ substances: when the 1st substance is renewed, no need to evaluate data related to the 2nd substance
- ▶ The assessment should focus only on the **new information** using the Guidance documents in force at the **time of application**




Key industry concerns

- **Early appointment of ZRMS**
 - choice of applicant or decision Steering Committee?
- **In case no change of GAP only resistance statement required ?**
- **Harmonisation of GAP's across the zone**
- **Check to ensure data protection is respected**
- **How to complete authorisations in the Zone, eg 1 crop missing, 1 country missing**



Post-AIR Timeline: AIR 3


**No GAP change, No residue definition change
not 'Category 4' studies**



EIF = Approval of active substance

Post-AIR Timeline: AIR 3

GAP change, need for Category 4 studies, eg Residue trials (seasonal studies)



EIF = Approval of active substance

Candidates for Substitution and comparative assessment

Candidates for Substitution

- ▶ **77 substances out of approx 400**
 - many more than envisaged as pragmatic (**10%**)
 - equates to 40% of products subject to C. Assessment
 - Multiple assessment with multiple reviews Post-AIR
- ▶ **Number of CFS will grow as substances are reviewed**
- ▶ **Need for clear communication from Commission and MS authorities**
 - substances already approved in EU after passing through one of most stringent regulatory systems

Comparative Assessment

- Applicable from **1 August 2015** with new applications
- Very little practical experience
- Industry participated to pilot projects in NLD, UK, AUT
- Many MS have not finalised national procedures yet
- Tendency for MS to follow guidance from CRD with adaptations




Comparative assessment

- ▶ **Derogation for New products for 5 years (Article 50.3) to support innovation**
 - New active substances
 - New mixture combinations
 - New crops/uses
- ▶ **Non-Chemical Methods**
 - Not necessarily preferable or safer in practice
 - Should be evaluated for safety and overall suitability
 - DEFRA have made comprehensive review



A Practical guide

For a crop and pest/fungus/weed combination: compare Candidate Product with Alternative(s)



Industry role in CA

- **Provide relevant arguments to MS to demonstrate that substitution should be avoided in order that**
 - Four modes of action for each solution maintained
 - Safeguard solutions for minor uses
 - Workload for evaluation is minimised
- **Pragmatic approach required to maintain farmers tool box**
 - Demonstrate benefits for PPP



Review of legislation

Review of EU legislation



Commission report in 2016

- DG SANTE ‘roadmap’– with public consultation in late 2015
- Consultant report to start in 2016, completed late 2016?

ECPA view

- Support joint review of both Regulations
 - Evaluate the implementation of the current legislation
 - Review options for future improvements
- Any future amendments should be based on the review
 - ***But we have some ideas...***
- **ECPA will however continue to focus on improving the workings of the current legislative frameworks**

Key areas for improvement

View of ECPA, IBMA, ECCA

- **Introduce a Data call-in process to ensure a predictable regulatory process**
- **Realistic timelines**
 - Experience has shown that they are not achievable without increased resources at EU/MS level
- **Decouple Active substance and Product Reviews**
- **Definitions & Scope of Regulation**
 - Compared to Fertiliser Regulation 2003/2003
- **Harmonisation across EU chemical legislation**
 - Pesticides, Biocides, REACH, Cosmetics



Data call-in process

How should it work?

Learn from US/Canadian system

- Need for new data/dossier update identified
- Agreement on data required (data call-in)
 - With cooperation: authorities, notifiers & NGO's
- Agreed submission date
- **Joint Data submission :all authorisation holders**
 - Linked to compulsory data access process
 - Submission required to remain on the market
 - Data 'protected' from date of submission
- Evaluation of dossier
- Renewal/amendment of approvals
 - Confirmatory data >> new data call-in

Data call-in process

Benefits

- Promotes cooperation for single dossier submission
- More predictable process (clarity on data required/expected)
- Resources and workload can be properly balanced
 - Submission linked to **scientific** need not deadline
- Removes need for AS approval extensions...
- Focus on new data and criteria
- Focus on issues and not active substances
 - Better comparison of submissions
 - Equal treatment?

Conclusion

▀ Article 43

- Pragmatic implementation
- Should not delay new innovative products

▀ Comparative Assessment

- Need more time for experience
- Pragmatic implementation to keep farmers toolbox

▀ Revision of Regulation 1107/2009

- Data call-in process to ensure efficient use of resources
- Revision of process for Article 43



Thank you for your attention

martyn.griffiths@bayer.com

